1. Khanna, D, Tashkin, DP, Denton, CP, et al. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med 2020; 201: 650–660.
Google Scholar | Crossref | Medline2. Denton, CP, Hughes, M, Gak, N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology 2016; 55(10): 1906–1910.
Google Scholar | Crossref | Medline3. Kowal-Bielecka, O, Fransen, J, Avouac, J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017; 76(8): 1327–1339.
Google Scholar | Crossref | Medline4. Hoffmann-Vold, A-M, Maher, TM, Philpot, EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatology 2020; 2: e71–e83.
Google Scholar | Crossref5. Hansell, DM, Goldin, JG, King, TE, et al. CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. Lancet Respir Med 2015; 3(6): 483–496.
Google Scholar | Crossref | Medline6. Oda, K, Ishimoto, H, Yatera, K, et al. High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respir Res 2014; 15: 10.
Google Scholar | Crossref | Medline7. Ley, B, Elicker, BM, Hartman, TE, et al. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology 2014; 273(2): 570–579.
Google Scholar | Crossref | Medline8. Kim, GHJ, Tashkin, DP, Lo, P, et al. Using transitional changes on HRCT to monitor the impact of cyclophosphamide or mycophenolate on systemic sclerosis-related interstitial lung disease. Arthritis Rheumatol 2019; 72: 316–325.
Google Scholar | Crossref | Medline9. Wu, X, Kim, GH, Salisbury, ML, et al. Computed tomographic biomarkers in idiopathic pulmonary fibrosis. The future of quantitative analysis. Am J Respir Crit Care Med 2019; 199: 12–21.
Google Scholar | Crossref | Medline10. Bernstein, EJ, Khanna, D, Lederer, DJ. Screening high-resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: a global survey of rheumatologists. Arthritis Rheumatol 2018; 70(6): 971–972.
Google Scholar | Crossref | Medline11. van den Hoogen, F, Khanna, D, Fransen, J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747–1755.
Google Scholar | Crossref | Medline12. Sanchez-Cano, D, Ortego-Centeno, N, Callejas, JL, et al. Interstitial lung disease in systemic sclerosis: data from the Spanish Scleroderma Study Group. Rheumatol Int 2018; 38(3): 363–374.
Google Scholar | Crossref | Medline13. Elhai, M, Meune, C, Boubaya, M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76(11): 1897–1905.
Google Scholar | Crossref | Medline14. Moore, OA, Goh, N, Corte, T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology 2013; 52(1): 155–160.
Google Scholar | Crossref | Medline15. Hoffmann-Vold, AM, Allanore, Y, Alves, M, et al. Progressive lung fibrosis in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Arthritis Rheumatol 2018; 70: A799.
Google Scholar16. Hoffman-Vold, A-M, Allanore, Y, Alves, M, et al. Prediction and frequency of progressive lung fibrosis in patients with systemic sclerosis-associated interstitial lung disease in the world’s largest database of patients with systemic sclerosis (EUSTAR). Am J Respir Crit Care Med 2019; 199: A5615 (Poster presented at the American Thoracic Society (abstract 12910), Dallas, TX), https://doi.org/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A5615
Google Scholar | Crossref17. Nihtyanova, SI, Schreiber, BE, Ong, VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66(6): 1625–1635.
Google Scholar | Crossref | Medline18. Liaskos, C, Marou, E, Simopoulou, T, et al. Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity 2017; 50(7): 414–421.
Google Scholar | Crossref | Medline19. Steen, V, Domsic, RT, Lucas, M, et al. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 2012; 64(9): 2986–2994.
Google Scholar | Crossref | Medline20. Zhang, XJ, Bonner, A, Hudson, M, et al. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis. J Rheumatol 2013; 40(6): 850–858.
Google Scholar | Crossref | Medline21. Winstone, TA, Assayag, D, Wilcox, PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014; 146(2): 422–436.
Google Scholar | Crossref | Medline22. Moore, OA, Proudman, SM, Goh, N, et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. Clin Exp Rheumatol 2015; 33(4, Suppl. 91): S111–S116.
Google Scholar | Medline23. Hoffmann-Vold, A-M, Aalokken, TM, Lund, MB, et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol 2015; 67(8): 2205–2212.
Google Scholar | Crossref | Medline24. Goh, NS, Desai, SR, Veeraraghavan, S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248–1254.
Google Scholar | Crossref | Medline25. Wangkaew, S, Euathrongchit, J, Wattanawittawas, P, et al. Correlation of delta high-resolution computed tomography (HRCT) score with delta clinical variables in early systemic sclerosis (SSc) patients. Quant Imaging Med Surg 2016; 6(4): 381–390.
Google Scholar | Crossref | Medline26. Wu, W, Jordan, S, Becker, MO, et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann Rheum Dis 2018; 77(9): 1326–1332.
Google Scholar | Crossref | Medline27. Guler, SA, Winstone, TA, Murphy, D, et al. Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression. Ann Am Thorac Soc 2018; 15(12): 1427–1433.
Google Scholar | Crossref | Medline28. Hoffmann-Vold, AM, Fretheim, H, Halse, AK, et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med 2019; 200: 1258–1266.
Google Scholar | Crossref | Medline29. Hoffmann-Vold, AM, Distler, O, Murray, B, et al. Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. RMD Open 2019; 5(1): e000826.
Google Scholar | Crossref | Medline30. Ariani, A, Silva, M, Bravi, E, et al. Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis. RMD Open 2019; 5(1): e000820.
Google Scholar | Crossref | Medline31. Champtiaux, N, Cottin, V, Chassagnon, G, et al. Combined pulmonary fibrosis and emphysema in systemic sclerosis: a syndrome associated with heavy morbidity and mortality. Semin Arthritis Rheum 2019; 49(1): 98–104.
Google Scholar | Crossref | Medline32. Chung, J, Walker, CM, Hobbs, S. Imaging features of systemic sclerosis-associated interstitial lung disease. J Vis Exp. Epub ahead of print 16 June 2020. DOI: 10.3791/60300.
Google Scholar | Crossref33. Suliman, YA, Dobrota, R, Huscher, D, et al. Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol 2015; 67(12): 3256–3261.
Google Scholar | Crossref | Medline34. Showalter, K, Hoffmann, A, Rouleau, G, et al. Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis. J Rheumatol 2018; 45(11): 1572–1576.
Google Scholar | Crossref | Medline35. Jacob, J, Bartholmai, BJ, Rajagopalan, S, et al. Predicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis. Am J Respir Crit Care Med 2018; 198: 767–776.
Google Scholar | Crossref | Medline36. Jacob, J, Hirani, N, van Moorsel, CHM, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J 2019; 53(1): 1800869.
Google Scholar | Crossref | Medline37. Griffiths, B, Miles, S, Moss, H, et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29(11): 2371–2378.
Google Scholar | Medline38. Jacob, J, Bartholmai, BJ, van Moorsel, CHM, et al. Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis. Eur Respir J 2019; 54(3): 1802341.
Google Scholar | Crossref | Medline39. Roth, MD, Tseng, C-H, Clements, PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 2011; 63(9): 2797–2808.
Google Scholar | Crossref | Medline40. Patiwetwitoon, S, Wangkaew, S, Euathrongchit, J, et al. High-resolution computed tomographic findings in systemic sclerosis-associated interstitial lung disease: comparison between diffuse and limited systemic sclerosis. J Clin Rheumatol 2012; 18(5): 229–233.
Google Scholar | Crossref | Medline41. Le Gouellec, N, Duhamel, A, Perez, T, et al. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. PLoS ONE 2017; 12(8): e0181692.
Google Scholar | Crossref | Medline42. Khanna, D, Nagaraja, V, Tseng, CH, et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther 2015; 17: 372.
Google Scholar | Crossref | Medline43. Launay, D, Remy-Jardin, M, Michon-Pasturel, U, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006; 33(9): 1789–1801.
Google Scholar | Medline44. Takei, R, Arita, M, Kumagai, S, et al. Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease. Respirology 2018; 23(4): 385–391.
Google Scholar | Crossref | Medline45. Goldin, JG, Kim, GHJ, Tseng, CH, et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II. Ann Am Thorac Soc 2018; 15(11): 1286–1295.
Google Scholar | Crossref | Medline46. Kim, HJ, Tashkin, DP, Gjertson, DW, et al. Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment. Ann Rheum Dis 2016; 75(7): 1367–1371.
Google Scholar | Crossref | Medline47. Kim, HJ, Brown, MS, Elashoff, R, et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol 2011; 21(12): 2455–2465.
Google Scholar | Crossref | Medline48. Zerhouni, EA, Naidich, DP, Stitik, FP, et al. Computed tomography of the pulmonary parenchyma. Part 2: interstitial disease. J Thorac Imaging 1985; 1: 54–64.
Google Scholar | Crossref | Medline